A Study to Evaluate Effectiveness and Safety of a TYK2 Inhibitor in Subjects With Moderate to Severe Plaque Psoriasis
Key facts
- Where
- Shanghai, ChinaSee the site
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 70 years old?
Where in China
- Shanghai Skin Disease HospitalShanghai, ChinaTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Usynova Pharmaceuticals Ltd.
- Trial code
- NCT07234591
- Record updated
- 18 November 2025
- Original description
A Study to evaluate efficacy and safety in subjects with moderate to severe Plaque Psoriasis treated with a TYK2 Inhibitor for 12 weeksRead full original descriptionShow less
A Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of a TYK2 Inhibitor in Subjects With Moderate to Severe Plaque Psoriasis
A Study to evaluate efficacy and safety in subjects with moderate to severe Plaque Psoriasis treated with a TYK2 Inhibitor for 12 weeks
Inclusion: Male and female, ages 18 to 70 years; Body weight >40 kg, body mass index (BMI) of 18 to 40 kg/m2; Clinical diagnosis of plaque psoriasis for ≥6 months before the Baseline visit; Women of childbearing potential (WOCBP) and males who are sexucally active must agree to follow instructions for method(s) of contraception.
Exclusion: Previously received tyrosine kinase 2 (TYK2) inhibitors; Previously received other psoriasis treatments such as biological agents, immunoregulators, or hormonal drugs within a specific period before administration, and the investigator deems it may affect the immunity of the subjects; Has participated in any clinical trials within 30 days or 5 half-lives of the drug before the first administration, or currently undergoing visits for other clinical trials; Has history of chronic disease that may affect the study, or acute or chronic severe infectious diseases, such as a history of active or inadequately treated latent tuberculosis infection, severe bone or joint infections within 6 months before screening, and other acute infectious diseases; Has known or suspected skin or systemic autoimmune diseases other than psoriasis and psoriatic arthritis; Other conditions that the investigator deems unsuitable for participation in this study; Other protocol defined inclusion/exclusion criteria could apply; Diagnosed with non-plaque psoriasis.